Ceribell, Inc. (CBLL)
NASDAQ:CBLL
Want to see CBLL full AI Analyst Report?
Top Page
Ceribell, Inc.
(NASDAQ:CBLL)
Select Model
Select Model
Rating:49Neutral
Price Target:
$18.50
▲(0.76% Upside)
Action:Reiterated
Date:05/14/26
The score is held back primarily by persistent losses and heavy cash burn despite strong revenue growth and high gross margins. Technical indicators also show weak momentum. These are partially offset by constructive earnings-call signals (raised guidance, strong Q1 execution, and solid liquidity) and a valuation profile that is difficult to assess due to negative earnings.
Positive Factors
Revenue Growth & Commercial Traction
Sustained 29% YoY revenue growth, a raised FY26 guide, and sequential gains indicate durable commercial momentum. Faster hospital adoption and utilization growth point to scalable demand and increasing share in the acute‑care EEG market, supporting mid‑term revenue visibility and TAM penetration.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow of roughly $49M TTM signals ongoing cash burn that will require external funding unless operating losses narrow. This persistent burn increases dilution and constrains optionality for aggressive commercial investment or M&A over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth & Commercial Traction
Sustained 29% YoY revenue growth, a raised FY26 guide, and sequential gains indicate durable commercial momentum. Faster hospital adoption and utilization growth point to scalable demand and increasing share in the acute‑care EEG market, supporting mid‑term revenue visibility and TAM penetration.
Read all positive factors
Ceribell, Inc. (CBLL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$700.80M
Dividend YieldN/A
Average Volume (3M)265.67K
Price to Earnings (P/E)―
Beta (1Y)0.94
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees281
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.63
Shares Outstanding37,942,700
10 Day Avg. Volume244,220
30 Day Avg. Volume265,666
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)5.16
Price to Sales (P/S)9.00
P/FCF Ratio-19.28
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue7.12
Enterprise Value/Gross Profit8.12
Enterprise Value/Ebitda-11.82
Forecast
1Y Price Target
$28.50Price Target Upside55.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$113.99M
Ceribell, Inc. Business Overview & Revenue Model
Company Description
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's pri...
How the Company Makes Money
null...
Ceribell, Inc. Earnings Call Summary
Earnings Call Date:May 11, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call presented strong commercial momentum and robust top-line growth (29% YoY revenue, record account additions, high 87% gross margin), alongside several strategic milestones (neonate/pediatric launches, delirium pilot with FDA clearance, favorable NTAP proposal, LVO Breakthrough designation) and a healthy cash position. Offsetting these positives are elevated operating expenses (+36% YoY), significant near-term litigation costs ($5.6M in Q1), a wider net loss ($19.7M), and continued adjusted EBITDA losses. Given the combination of accelerating revenue/market expansion and manageable but notable near-term expense pressures, the tone is constructive with near-term investment-driven profitability headwinds.Positive Updates
Strong Top-Line Growth
Total revenue of $26.5M in Q1 2026, up 29% year-over-year and 7% sequentially; full-year 2026 revenue guidance raised to $112M–$116M (up from $111M–$115M), implying 26%–30% growth over 2025.
Negative Updates
Rising Operating Expenses
Total operating expenses were $43.9M in Q1 2026, a 36% increase year-over-year (from $32.2M), driven by higher sales & marketing and R&D investments to support commercial expansion and product development.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Top-Line Growth
Total revenue of $26.5M in Q1 2026, up 29% year-over-year and 7% sequentially; full-year 2026 revenue guidance raised to $112M–$116M (up from $111M–$115M), implying 26%–30% growth over 2025.
Read all positive updates
Company Guidance
CeriBell raised full‑year 2026 revenue guidance to $112–$116 million (up from $111–$115M), implying 26%–30% growth over 2025, after a strong Q1: revenue $26.5M (+29% YoY, +7% sequential) comprised of product $20.2M and subscription $6.3M (both +29% YoY), with 680 hospitals (+33 net adds) and record headband utilization; Q1 gross margin was 87% (vs. 88% LY) and management expects to sustain gross margins in the high‑80% range in 2026 despite elevated China tariffs as Vietnam manufacturing ramps; Q1 operating expense was $43.9M (+36%), net loss $19.7M (‑$0.52/sh; avg. 37.7M shares), adjusted EBITDA loss $11.2M, cash and marketable securities $141.2M, TAM ≈ $3.5B, and key catalysts include a proposed NTAP of up to $2,171/patient (final rule Aug ’26, effective 10/1/26) and full delirium launch targeted Q4 ’26–Q1 ’27.Ceribell, Inc. Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
64
Positive
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 95.07M | 89.06M | 65.44M | 45.23M | 25.92M |
| Gross Profit | 83.39M | 78.27M | 56.75M | 38.16M | 21.49M |
| EBITDA | -57.27M | -50.18M | -37.32M | -26.51M | -35.06M |
| Net Income | -60.37M | -53.41M | -40.45M | -29.46M | -37.16M |
Balance Sheet | |||||
| Total Assets | 178.08M | 195.80M | 225.41M | 58.92M | 86.46M |
| Cash, Cash Equivalents and Short-Term Investments | 141.18M | 159.26M | 194.37M | 34.49M | 68.23M |
| Total Debt | 22.12M | 22.28M | 21.96M | 14.20M | 18.22M |
| Total Liabilities | 37.27M | 40.47M | 34.25M | 171.17M | 172.86M |
| Stockholders Equity | 140.81M | 155.34M | 191.16M | -112.25M | -86.40M |
Cash Flow | |||||
| Free Cash Flow | -49.60M | -41.58M | -36.38M | -30.14M | -32.52M |
| Operating Cash Flow | -48.85M | -40.81M | -35.04M | -29.16M | -32.00M |
| Investing Cash Flow | -66.09M | -118.14M | -1.60M | -1.76M | -1.40M |
| Financing Cash Flow | 6.83M | 5.05M | 196.52M | -2.82M | 49.80M |
Ceribell, Inc. Technical Analysis
Positive
18.36
Price Trends
19.04
Negative
19.28
Negative
17.37
Positive
Market Momentum
-0.17
Negative
50.19
Neutral
60.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CBLL, the sentiment is Positive. The current price of 18.36 is above the 20-day moving average (MA) of 18.05, below the 50-day MA of 19.04, and above the 200-day MA of 17.37, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 50.19 is Neutral, neither overbought nor oversold. The STOCH value of 60.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CBLL.
Ceribell, Inc. Risk Analysis
Ceribell, Inc. disclosed 76 risk factors in its most recent earnings report. Ceribell, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Ceribell, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $404.59M | 752.53 | 0.51% | ― | 67.95% | ― | |
61 Neutral | $1.45B | -18.75 | -36.79% | ― | 20.20% | -0.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $700.80M | -11.52 | -38.19% | ― | ― | ― | |
47 Neutral | $464.78M | -5.59 | -17.61% | ― | 3.63% | -93.57% | |
47 Neutral | $511.40M | -6.89 | -20.77% | ― | 3.61% | -568.29% |
* Healthcare Sector Average
CBLL
Ceribell, Inc.
18.47
1.25
7.26%
DCTH
Delcath Systems
11.72
-3.71
-24.04%
VREX
Varex Imaging
11.04
2.77
33.49%
BFLY
Butterfly Network
5.54
3.23
139.83%
CTKB
Cytek Biosciences
3.96
0.66
20.00%
Ceribell, Inc. Corporate Events
Executive/Board ChangesShareholder Meetings
Ceribell Announces Director Elections at 2026 Annual Meeting
Neutral
Jun 2, 2026
CeriBell, Inc. held its 2026 Annual Meeting of Stockholders on June 2, 2026, where shareholders elected Josef Parvizi, M.D., Ph.D., and Rebecca Robertson as Class II directors to serve until the 2029 Annual Meeting and until their successors are d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.